<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36008232</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41 Suppl 1</Volume><PubDate><Year>2023</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020.</ArticleTitle><Pagination><StartPage>A19</StartPage><EndPage>A24</EndPage><MedlinePgn>A19-A24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2022.08.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(22)00962-8</ELocationID><Abstract><AbstractText>The number and geographic breadth of circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks detected after the withdrawal of type 2 containing oral polio vaccine (April 2016) have exceeded forecasts.Using Acute Flaccid Paralysis (AFP) investigations and environmental surveillance (ES) data from the Global Polio Laboratory Network, we summarize the epidemiology of cVDPV2 outbreaks. Between 01 January 2016 to 31 December 2020, a total of 68 unique cVDPV2 genetic emergences were detected across 34 countries. The cVDPV2 outbreaks have been associated with 1596 acute flaccid paralysis cases across four World Health Organization regions: 962/1596 (60.3%) cases occurred in African Region; 619/1596 (38.8%) in the Eastern Mediterranean Region; 14/1596 (0.9%) in Western-Pacific Region; and 1/1596 (0.1%) in the European Region. As the majority of the cVDPV2 outbreaks have been seeded through monovalent type 2 oral poliovirus vaccine (mOPV2) use in outbreak responses, the introduction of the more stable novel oral poliovirus vaccine will be instrumental in stopping emergence of new cVDPV2 lineages.</AbstractText><CopyrightInformation>Copyright Â© 2022. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macklin</LastName><ForeName>Grace R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organisation, Geneva, Switzerland; London School of Hygiene and Tropical Medicine, London, UK. Electronic address: mackling@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goel</LastName><ForeName>Ajay K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organisation, Geneva, Switzerland. Electronic address: goela@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organisation, Geneva, Switzerland. Electronic address: macho@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tallis</LastName><ForeName>Graham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organisation, Geneva, Switzerland. Electronic address: tallisg@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Jamal A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organisation, Geneva, Switzerland. Electronic address: ahmedjam@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Reilly</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, London, UK. Electronic address: kathleen.oreilly@lshtm.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassly</LastName><ForeName>Nicholas C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Imperial College London, London, UK. Electronic address: n.grassly@imperial.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diop</LastName><ForeName>Ousmane M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>Polio Eradication, World Health Organisation, Geneva, Switzerland. Electronic address: diopo@who.int.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>MR/R015600/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000629404">acute flaccid myelitis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute flaccid paralysis</Keyword><Keyword MajorTopicYN="N">Circulating vaccine-derived poliovirus</Keyword><Keyword MajorTopicYN="N">Outbreaks</Keyword><Keyword MajorTopicYN="N">Polio</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>22</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36008232</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.08.008</ArticleId><ArticleId IdType="pii">S0264-410X(22)00962-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle>